Patent ID: 9616104
Date: 2017-04-11
CPC Classifications: A61K,A61P

Claim:
1. A method of inhibiting a proinflammatory agent in a patient having osteoarthritis, the method comprising administering 0.25 mg/kg to 20 mg/kg of XPro®-1595 in a drug depot to a target tissue site at or near the joint, wherein the proinflammatory agent comprises MMP-3, nitrous oxide, IL-1 or combinations thereof and the drug depot comprises poly (lactide-co-glycolide) (PLGA) and polyethylene glycol (PEG) having a molar ratio of 4:1 and the XPro®-1595 is administered by a continuous infusion over 24 to 48 hours or the XPro®-1595 is released over at least 3 days to 6 months.